Market Overview

UPDATE: Goldman Sachs Cuts PT to $4.60 on ZELTIQ Aesthetics Following Q4 Results

Share:
Related ZLTQ
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Piper Jaffray Starts Zeltiq At Overweight, Sees Upside Of $35/Share

Goldman Sachs reiterated its Neutral rating on ZELTIQ Aesthetics (NASDAQ: ZLTQ) and reduced its price target from $5 to $4.60.

Goldman Sachs noted, "Zeltiq announced preliminary 4Q2012 results that were well below our estimates and consensus. … Zeltiq is still trying to figure out its go-to-market strategy and how to target the most appropriate customer. We think this lack of strategic direction over the past two quarters has been the primary culprit of poor sales execution. We also see competitive pressures (especially Solta's LipoSonix product) as having impacted results, a trend that should remain a headwind for the foreseeable future."

ZELTIQ Aesthetics closed at $4.74 on Friday.

Latest Ratings for ZLTQ

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015Piper JaffrayInitiates Coverage onOverweight
Jun 2015Goldman SachsUpgradesNeutralBuy

View More Analyst Ratings for ZLTQ
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ZLTQ)

Get Benzinga's Newsletters